NCT06239532: HAIC Sequential TAE Combined With Tislelizumab and Surufatinib in Unresectable Intrahepatic Cholangiocarcinoma
- State
- Under way
- Phase
- Phase 2
- People
- 28 taking part
- Started
- 27 Sep 2022
- Primary completion
- 31 Dec 2024
- Arms
- TAE+HAIC+Tislelizumab+Surufatinib
- Results
- None posted
- 27 Sep 2022: Trial started
- 2 Feb 2024: Trial registered